期刊
VACCINE
卷 29, 期 15, 页码 2720-2726出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2011.01.083
关键词
Malaria transmission-blocking vaccine; Human adenovirus
资金
- Founding Research Centers for Emerging and Reemerging Infectious Diseases from The Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [19406009, 20590425, 21022034]
- Okinawa Industry Promotion Public Corporation
- Institute of Tropical Medicine, Nagasaki University
- Grants-in-Aid for Scientific Research [23590490, 19406009, 20590425] Funding Source: KAKEN
Adjuvants or delivery vehicles are essential components to expedite malaria vaccine development. In this study, replication-defective human adenovirus serotype 5 (rAd) was genetically engineered to express the Plasmodium vivax ookinete surface protein (OSP), Pvs25 (AdPvs25). BALB/c mice immunized with the AdPvs25 through various routes including intramuscular, subcutaneous and intranasal routes were analyzed for induction of antigen-specific transmission-blocking immunity. Parenteral but not mucosal immunization induced high serum immunoglobulin G (IgG) responses specific to P. vivax ookinetes isolated from P. vivax volunteer patients from Thailand. The membrane feeding assay revealed that antisera conferred a transmission blockade of up to 99% reduction in the average oocyst numbers per mosquito, while immunization with a rAd expressing Pfs25 from Plasmodium falciparum, a homolog of Pvs25, conferred only a background level of blockade, suggesting that a species-specific transmission-blocking immunity was induced. Vaccine efficacy of AdPvs25 was slightly higher than to a recombinant Pvs25 protein mixed with aluminum hydroxide, but less efficacious than the protein emulsified with incomplete Freund's adjuvant. This study, the first preclinical evaluation of adenovirus-vectored malaria OSPs, implicates a potential inclusion of malaria transmission-blocking vaccine antigens in viral vector systems. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据